Revision as of 12:34, 3 September 2011 editCheMoBot (talk | contribs)Bots141,565 edits Updating {{drugbox}} (no changed fields - updated 'ChemSpiderID_Ref', 'DrugBank_Ref', 'UNII_Ref', 'ChEMBL_Ref', 'ChEBI_Ref', 'KEGG_Ref', 'StdInChI_Ref', 'StdInChIKey_Ref', 'ChEBI_Ref') per Chem/Drugbox validation (report [[Misplaced Pages← Previous edit | Revision as of 22:34, 13 November 2011 edit undoThe chemistds (talk | contribs)Extended confirmed users5,761 edits No ChemSpider ID for this recordNext edit → | ||
Line 31: | Line 31: | ||
| DrugBank_Ref = {{drugbankcite|correct|drugbank}} | | DrugBank_Ref = {{drugbankcite|correct|drugbank}} | ||
| DrugBank = | | DrugBank = | ||
| ChemSpiderID = NA | |||
<!--Chemical data--> | <!--Chemical data--> |
Revision as of 22:34, 13 November 2011
This article is an orphan, as no other articles link to it. Please introduce links to this page from related articles; try the Find link tool for suggestions. (December 2009) |
Clinical data | |
---|---|
ATC code |
|
Identifiers | |
IUPAC name
| |
CAS Number | |
ChemSpider | |
Chemical and physical data | |
Molar mass | Antibodies in the 144.8 -148.8 kDa range |
(verify) |
Rozrolimupab (Sym001) is a polyclonal antibody used in the treatment of autoimmune thrombocytopenic purpura, prevention of isoimmunization in Rh-negative pregnant women.
This drug was developed by Symphogen A/S.
References
- STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL - ROZROLIMUPAB, American Medical Association.
This pharmacology-related article is a stub. You can help Misplaced Pages by expanding it. |